Objective: Research on the relationships between different hormone therapy doses, formulation and routes of delivery, and subsequent breast cancer incidence has been limited. This study directly compared different estrogen doses, formulations, and route of delivery of estrogen alone among women with a hysterectomy in relation to invasive breast cancer incidence.
O bservational epidemiological studies have consistently reported increased breast cancer risk associated with postmenopausal hormone therapy (HT) use. 1, 2 However, Women's Health Initiative (WHI) results indicate that breast cancer risks differ between estrogen plus progestin, 3 and estrogen alone. 4 There is limited research on the relationship between estrogen dose, route of delivery, and formulation (bioidentical vs synthetic) and the risk of breast cancer.
In the WHI clinical trials (WHI-CT), breast cancer risk during the intervention phase (ended March 31, 2005) was increased in the estrogen plus progestin arm (hazard ratio [HR] 1.25, 95% confidence interval [CI] 1.07-1.46), 3 but not in the estrogen-alone arm (RR 0.77, 95% CI 0.57-1.01). 4, 5 In follow-up analysis of the health outcomes from the estrogenalone trial after 10.7 years (including a median 5.9 years for the intervention phase), women on estrogen therapy alone had a significantly lower breast cancer risk compared with those on placebo (HR 0.77, 95% CI 0.62-0.95). 6 Furthermore, in women who developed breast cancer, the risk of dying was lower in women who took estrogen compared with those on placebo. More recently, breast cancer mortality results for women randomized to conjugated equine estrogen (CEE)-alone were found to have statistically significant lower mortality rates after 18 years in follow-up versus placebo (HR 0.55, 95% CI 0.33-0.92). 7 It is unknown whether the lower breast cancer risk in the estrogen-alone trial extends to other doses, routes of delivery, and formulations.
To date, no randomized clinical trials have provided headto-head comparisons of different doses or formulations of estrogen (eg, CEE vs 17-b estradiol [E 2 ]), in relation to breast cancer outcomes. Animal models have suggested that the standard doses of CEE may result in less estrogen-induced epithelial proliferation in the breast compared with E 2 , but these results have yet been replicated in humans. 8 One Finnish study assessed the incidence of breast cancer in women using oral or transdermal E 2 and did not find a difference in observed risk by route of delivery; although this study did not control for confounders such as parity, age at first birth, and weight. 9 Even though these questions are of great clinical interest, it remains unknown whether HT dose, formulations, or route of delivery influences breast cancer incidence.
The purpose of this study was to evaluate relationships between different estrogen doses, formulations, and route of delivery in women with a hysterectomy on estrogen-alone HT in relation to invasive breast cancer incidence in the WHI Observational Study WHI-OS. Further, a goal was to determine whether results varied by time since menopause onset (<10 years, !10 years) for estrogen initiation, as current menopause guidelines recommend initiating HT within 10 years in healthy menopausal women for menopause related symptoms. 10 
METHODS
The WHI-OS is a large multicenter prospective cohort study conducted at 40 US sites. The details of the scientific rationale, eligibility criteria, and design of the WHI-OS have been previously published. 11 Briefly, 93,676 postmenopausal women aged 50 to 79 years were recruited between September 1, 1993 and December 31, 1998. Annual follow-up by mailed self-administered questionnaires and completed annual medical histories, confirmed by medical record review, and detailed assessments of hormone use were obtained through September 12, 2005 . Data were uniformly collected from participants according to a standardized institutional review board-approved protocol by trained study staff. All participants provided written informed consent for this research study at the time of enrollment.
For these analyses, 39,147 women had a hysterectomy before baseline. Study participants were excluded if they had a history of breast cancer (n ¼ 2,206), no mammogram reported within 2 years of baseline (n ¼ 6,224), missing information regarding baseline HT use (n ¼ 45), and those reporting current use of both estrogen plus progestin by women with previous hysterectomy (n ¼ 792). Additional exclusion that occurred at baseline or during follow-up included: use of estrogen with testosterone (n ¼ 1,507), use of dehydroepiandrosterone (DHEA) (n ¼ 620), phytoestrogen pills or creams (n ¼ 1,395), yam pill (n ¼ 176), or progesterone creams (n ¼ 747). The number of women remaining was 26,525.
For this study, breast cancer was defined as invasive breast cancer and did not include breast cancer in situ. Information on breast cancer was collected at annual contacts. Breast cancers were initially verified by medical record review by centrally trained physician adjudicators at each clinical center with final adjudication and coding performed centrally by WHI cancer coders.
Oral HT estrogen doses were defined as: low-dose CEE <0.625 mg; conventional-dose CEE 0.625 mg; and high-dose CEE >0.625 mg. Hormone formulation categories were defined as oral E 2 and oral CEE. Transdermal estrogen categorization included all dose formulations. Mean duration of HT use before enrollment plus years of use of current formulation at baseline through follow-up was calculated for each formulation.
Statistical analysis
Descriptive statistics of the study sample characteristics were reported using mean AE standard deviation or frequency, by HT type and dose. Cox proportional hazards models were used to estimate HRs and 95% CIs between different doses, routes of delivery, and formulations of HT and breast cancer incidence directly compared with conventional CEE dose. Time to breast cancer incidence was computed from date of enrollment to date of first breast cancer event, and censored by date of death, date of last study follow-up, or September 12, 2005 , whichever occurred first. Annual follow-up data were collected on HT with a mean follow-up time of 8.2 years. For each follow-up year, the type of hormone used was categorized as nonuser, oral E 2 , transdermal, oral low-dose CEE, oral conventional-dose CEE, oral high-dose CEE, and other.
SHUFELT ET AL
The HT exposure begins with the baseline information, and at each subsequent data collection, the type and dose is updated; if HT is stopped, the participant becomes a former user, and remains a never user if no use is reported during follow-up. To increase the precision of the standard error estimates, the models include all participants including the never and former users. All analyses were stratified by baseline at 5-year age intervals.
Variables considered as potential confounders or effect modifiers were included as covariates in the model and included age (linear), race/ethnicity (White, Black, Hispanic, Asian/Pacific Islander, other), smoking (never, former, current), quartiles of total recreational physical activity measured in metabolic equivalent of task-h/wk, body mass index (BMI) categories (<25, 25-<30, !30 kg/m 2 ), BMI (linear kg/m 2 ), treated diabetes (no, yes), oophorectomy (no, partial, bilateral), education (five categories, Table 1 ) and household income (six categories, Table 1 ), alcohol consumption (six categories, Table 1 ), parity (six categories, Table 1 ), cumulative frequency of mammography, Gail risk score for breast cancer (this takes into account family history, menarche, and age at first birth), and prior HT use (no, yes). Analyses were adjusted for frequency of mammography during follow-up using a time-dependent cumulative count of annually reported mammography. HRs and 95% CIs were estimated by years since menopause (<10 vs >10) and gap time, where years since menopause is the difference between age at menopause and age at WHI enrollment, and gap time is the difference between age at menopause and age first used HT. All analyses were conducted using SAS 9.2 (SAS Institute, Inc., Cary, NC). All P values were two-sided tests, and values less than 0.05 were considered statistically significant. Table 1 summarizes the demographic characteristics of the analytic sample of women with hysterectomy at baseline (study enrollment), stratified by the comparison groups according to dose of CEE, HT formulation, and route of delivery. Mean duration of follow-up for the WHI-OS in these analyses was 8.2 years. Mean duration of HT use was 18.5 years for conventional-dose CEE, 17.4 years for lowdose CEE, 19.3 years for high-dose CEE, 14.7 years for oral E 2 , and 14.0 years for transdermal use.
RESULTS
At baseline, 5,990 (22.5%) women with a hysterectomy had never used HT. Among women with a hysterectomy using high-dose CEE, the age at menopause was younger (43.1 years) with higher rates of bilateral oophorectomy. Women using low-dose CEE had a higher mean baseline Gail score (2.08) (5-year risk of breast cancer) compared with those using conventional or high-dose CEE (1.68). Among the women using CEE formulation, 846 (7%) were on low-dose CEE, 2,004 (16%) were on high-dose CEE, and the remainder (9, 903 [77%]) were on conventionaldose CEE. There were 1,134 women using transdermal estrogen, a number similar to women using oral E 2 . The mean age at enrollment was 65.4 (7.3) years for the never users and slightly lower in the hormone users, with the lowest age at follow-up seen in the transdermal E 2 users, 60.6 (6.8) years. Women who used HT tended to have lower BMI, higher educational and household income levels, and were more likely to have had bilateral oophorectomy. These and other variables were included in multivariate models.
Overall, the absolute risk of invasive breast cancer was 43 per 10,000 person-years in women with hysterectomy using CEE-alone over the 8-year follow-up. The risk was slightly higher in women using CEE alone <10 years since menopause (45 per 10,000 person-years) compared with >10 years since menopause (42 per 10,000 person-years); however, this difference was not statistically significant.
Direct comparison: route of delivery
After adjustment for age, breast cancer risk factors, education, and household income, the transdermal route of delivery was associated with a slight but nonsignificant reduction in risk of breast cancer compared with oral conventional-dose CEE (RR 0.75, 95% CI 0.47, 1.19) ( Table 2) . Although the relatively small number of transdermal users likely limited power, this finding was consistent regardless of years since menopause.
Direct comparison: oral HT dose
After adjustment for breast cancer risk factors, women with a hysterectomy who used oral low-dose CEE had similar rates of breast cancer compared with women who used oral conventional-dose of CEE (Table 3 ). There was also no difference in breast cancer risk when stratified by years since menopause in women with a hysterectomy (<10 vs !10 years). There was also no difference in invasive breast cancer risk in the use of high-dose CEE when compared with the conventional-dose CEE overall and based on years since menopause (Table 3) . However, for all analyses, due to the limited sample size among the groups, statistical power was likely greatest for conventional-dose CEE, and limited for the high and low-dose HT.
Direct comparison: HT formulation
Analysis by estrogen type, E 2 versus CEE, suggested that oral E 2 may be associated with higher rates of breast cancer incidence in women with a hysterectomy than conventionaldose CEE (HR 1.20, 95% CI 0.84, 1.39), but the differences were not statistically significant (Table 4) . This difference was more pronounced <10 years since menopause, but still not significant (HR 1.46, 95% CI 0.78, 2.73).
For HT dose, formulation and route of delivery analyses were conducted to compare HT by gap time from menopause to first use of HT (<5 vs !5 years). HRs were not significantly increased or decreased, relative to conventional-dose CEE, for women in either gap-time group, and interaction tests by gap time were not statistically significant (see Appendix A, http://links.lww.com/MENO/A308). Statistical power for these analyses, however, was limited. SHUFELT ET AL DISCUSSION Our results indicate that invasive breast cancer risk did not differ in women with a hysterectomy using estrogen-alone when directly comparing different estrogen doses, formulations, and routes of delivery to the conventional oral CEE dose. Low-dose CEE was associated with a similar risk when compared with conventional dose, regardless of years since menopause. Our results suggest that transdermal E 2 may confer a slightly less risk of breast cancer than oral conventional dose; however, sample size likely contributed to this analysis being underpowered. Oral E 2 compared with conventional-dose CEE was associated with a trend toward higher breast cancer incidence, specifically within the first 10 years since menopause, and further work is needed in larger sample sizes. The totality of these findings support the hypothesis that the lower breast cancer risk found in the WHI CEE-alone trial may extend to lower doses of CEE-alone, and also transdermal route of delivery.
ESTROGEN THERAPY AND INVASIVE BREAST CANCER
To date, many observational and clinical studies have found higher rates of breast cancer using estrogen-alone even stratified by dose, formulation, or route of delivery. In the Million Women's Study, breast cancer risk using estrogenalone compared with never users was increased, regardless of route of delivery or CEE dose (transdermal E-alone: RR 1.24, 95% CI 1.11-1.39; vs oral E-alone: RR 1.32, 95% CI 1.21-1.45) and (CEE <0.625 mg: RR 1.25, 95% CI 1.11-1.41; vs CEE >0.625 mg: RR 1.36, 95% CI 1.14-1.61). 12 In the French E3N Cohort study, there was no difference between route of delivery comparing oral and transdermal, and both had a nonsignificant increased risk (oral E-alone: RR 1.32, 95% CI 0.76-2.29; vs transdermal E-alone: RR 1.28, 95% CI 0.98-1.69), with a follow-up of 8.1 years. 13 In a Finnish registry report of 85,000 women, oral and transdermal estrogen-alone had similar breast cancer risk with no increased risk <5 years of use (overall HR 0.93, 95% CI 0.80-1.04); however, after >5 years regardless of dose, both oral and transdermal estrogen-alone had increased risk for breast cancer (overall HR 1.44, 95% CI 1.29-1.59). 14 A majority of breast cancers (80%) are estrogen receptor positive, so the concept that estrogen-alone therapy may decrease the risk of invasive breast cancer appears contradictory. 15 Menopause HT after breast cancer has also been associated with more invasive breast cancer and increased rates of recurrence. [16] [17] [18] Furthermore, antiestrogen drugs used to block estrogen production (aromatase inhibitors), block ovarian function (gonadotropin-relating hormone agonists), or block the effect at the estrogen receptor (selective estrogen receptor modulators) are current standards of care for breast cancer treatment. 19 However, before development of these agents, the standard of care for metastatic postmenopausal breast cancer treatment was high-dose synthetic estrogen therapy (E 2 6-30 mg/d). 20, 21 The remission of breast cancer with high-dose estrogen therapy increased relative to the number of years since menopause when treatment was initiated, leading to the hypothesis that the mechanism of action is antitumor activity through apoptosis in long-term estrogendeprived breast cancer cells. 21, 22 Recent attention has focused on the difference between oral estrogen compared with transdermal delivery with respect to first pass metabolism, pharmacokinetics, and inflammatory markers in the liver. [23] [24] [25] Oral estrogens first metabolize in the liver sinusoids, resulting in higher conversion of E 2 to estrone, as opposed to transdermal estrogens that avoid first pass metabolism, providing a lower and constant dose of estrogen with a more physiologic ratio of E 2 to estrone. 24 While the association with ''first pass'' has been evaluated with respect to cardiovascular outcomes, 26 the association with breast cancer remains unclear.
The limitation of our study includes the observational design that cannot address causal inferences. We cannot exclude the possibility of confounding due to selection bias related to the type of HT used. Another limitation includes the small number of women using transdermal or low-dose estrogen, resulting in large CIs, making interpretation of these results challenging. Finally, we recognize that adjusting for breast cancer-related characteristics such as Gail risk score at baseline may potentially lead to residual confounding in our observation cohort and may underestimate breast cancer risk.
CONCLUSIONS
To date, our analysis is one of the largest studies to address the relation of dose, formulation, and route of delivery with estrogen-alone and invasive breast cancer. Our results suggest that invasive breast cancer risk does not differ appreciably in users of low-dose versus conventional-dose CEE. We did not observe differences in invasive breast cancer risk between oral E 2 or transdermal E 2 users, compared with conventionaldose oral CEE; however, relatively low prevalence of SHUFELT ET AL transdermal use likely limited power for this comparison. These findings suggest that the lower risk of breast cancer found in the WHI CEE-alone trial may extend to lower doses of CEE, and also transdermal route of delivery; however, we recognize that this study finding is limited by sample size. Future investigation should be focused on different doses of CEE and comparative analyses with transdermal and oral E 2 .
